Amyloid and dopamine transporter imaging in mild cognitive deficit and risk for Lewy body disease

Takeaway

  • A large proportion of patients with mild cognitive impairment (MCI) and at least one core feature of Lewy body dementia (LBD) are characterized by low amyloid-β deposition and reduced dopamine (DA) activity.

Why this matters

  • An initial phase of LBD comprising MCI with one or more core features of LBD that may be present prior to a clinically probable LBD diagnosis has recently been formulated as the key prodromal phenotype (MCI-LB); however, the impact of the co-existing underlying pathology on clinical phenotype is unknown.

  • The association of amyloid and DA biomarkers with MCI-LB highlights the need for further longitudinal studies to investigate the trajectory of these and other biomarkers and linkage with disease progression.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.